Key facts
- This page summarizes Joan Lau's Form 4 filing for Renovacor, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 05 Dec 2022, 20:23.
Joan Lau - 01 Dec 2022 Form 4 Insider Report for Renovacor, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 01 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Dec 2022, 20:23:45 UTC
- Prior SEC filing
- 27 May 2022
- Next SEC filing
- 09 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph Carroll, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joan Lau filed Form 4 for Renovacor, Inc. on 05 Dec 2022.
Change
- Previous filing in this sequence was filed on 27 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCOR
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- $0
- Shares
- -24,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,000
- Exercise price
- Footnotes
- F1, F2
RCOR
transaction
Derivative
Stock Option
Disposed to Issuer
- Transaction value
- $0
- Shares
- -12,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 01 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Joan Lau is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Represents Company Options (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
Footnote F2
Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.